The GLP-1 medicines semaglutide and tirzepatide do not alter disease-related pathology, behaviour or cognitive function in 5XFAD and APP/PS1 mice

Authors:

Abstract
No abstract available
Funding Information
  • Novo Nordisk AS
  • CIHR

This publication has 44 references indexed in Scilit: